04.11.2015 MediClin AG  DE0006595101

DGAP-News: MediClin AG: In the first nine months of the 2015 financial year, Group sales increased by 2.9 % up to EUR 414.4 mill. and the Group operating result improved from EUR 12.2 mill. to EUR 17.4 mill.


 
DGAP-News: MediClin AG / Key word(s): 9-month figures MediClin AG: In the first nine months of the 2015 financial year, Group sales increased by 2.9 % up to EUR 414.4 mill. and the Group operating result improved from EUR 12.2 mill. to EUR 17.4 mill. 04.11.2015 / 15:21 --------------------------------------------------------------------- MediClin: In the first nine months of the 2015 financial year, Group sales increased by 2.9 % up to EUR 414.4 mill. and the Group operating result improved from EUR 12.2 mill. to EUR 17.4 mill. Offenburg, November 4, 2015 - In the first nine months of the 2015 financial year, MEDICLIN Aktiengesellschaft (MediClin) achieved Group sales of EUR 414.4 mill. (9M 2014: EUR 402.8 mill.) thus being EUR 11.6 mill. or 2.9 % above the comparable period of the previous year. Group occupancy rate amounted to 87.7 % (9M 2014: 87.6 %). Raw materials and consumables used declined by EUR 3.1 mill. against previous year's value. Staff costs increased by EUR 7.7 mill. primarily due to the higher headcount. Depreciation and amortisation were up EUR 0.5 mill. and other operating expenses were up EUR 1.6 mill. on the respective previous years values. The Group operating result improved by EUR 5.2 mill. up from EUR 12.2 mill. to EUR 17.4 mill. and the consolidated result attributable to shareholders of MediClin AG increased by EUR 4.5 mill. from EUR 8.0 mill. to EUR 12.5 mill. compared to the previous year's period. Business development in the segments In the Post-acute segment, the good sales development of the previous quarters also continued in the third quarter of 2015. Sales in the acute segment were only EUR 0.5 mill. below the previous year's comparable quarter in the third quarter of 2015 (Q1 2015: EUR -1.3 mill.; Q2 2015: EUR -0.8 mill.), indicating an improvement in the sales performance. This is also supported by the number of cases, which increased again compared to the second quarter of 2015, nearly reaching the level of the third quarter of 2014. A comparison with the first nine months of the previous year reveals that sales in the post-acute segment rose by EUR 13.3 mill. (+5.7 %) based on a similar occupancy level as in the previous year and a slightly longer length of stay. Due to a lower number of cases and case mix points, sales in the acute segment were EUR 2.6 mill. (-1.7 %) lower than the previous year's value. A slight increase in occupancy led to a EUR 0.6 mill. increase(+6.6 %) in sales in the nursing care business area. Also in the nine-month view higher sales in the post-acute segment let to an increase of the segment result from EUR 10.8 mill. to EUR 15.8 mill. In the acute segment the decline in sales could be offset by lower expenses, so that a segment result of EUR 7.2 mill. could be achieved, being EUR 0.5 mill. above previous year's value. In the first nine months of the 2015 financial year, EUR 20.0 mill. (gross) was invested, thereof financed with subsidies EUR 1.7 mill. (9M 2014: EUR 14.2 mill. thereof with subsidies EUR 3.0 mill.). Cash and cash equivalents as of 30 September 2015 amounted to EUR 30.2 mill. (31.12.2014: EUR 26.3 mill.). The equity ratio was 49.1% (31.12.2014: 48.2 %). MediClin employed on average 6,500 employees (9M 2014: 6,405 employees), calculated on the basis of full-time staff, in the first nine months of the 2015 financial year. Outlook The business performance in the first nine months of the 2015 financial year indicates that the sales target of 3.0 % growth announced for the Group will be presumably reached. As for earnings, the Management Board assumes that Group EBIT will range between EUR 19 mill. and EUR 21 mill., provided the post-acute segment continues to perform well. The post-acute segment is expected to reach its sales and earnings targets. In the acute segment, the Management Board expects a sales decline, but assumes that the earnings target for the segment will be achieved thanks to process and cost optimisation measures. The interim report as of September 30, 2015 will be available in German and English from November 6, 2015 under www.mediclin.de. About MediClin AG (Ticker: MED; WKN: 659 510) MediClin AG is a nation-wide clinic operator and large provider of services in the area of Psycho- and Neuro-sciences as well as Orthopaedic. With 34 clinics, 7 nursing care facilities and 8 medical care centres in 11 federal states MediClin has a total capacity of approximately 8,000 beds. MediClins' facilities include acute care clinics, i.e., general hospitals, special treatment facilities, specialised hospitals and clinics for post-acute treatment and medical rehabilitation. MediClin has approximately 9,000 employees. MediClin ─ a company of the Asklepios Group --------------------------------------------------------------------- 04.11.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: MediClin AG Okenstraße 27 77652 Offenburg Germany Phone: +49 (0)781 488-189 Fax: +49 (0)781 488-184 E-mail: [email protected] Internet: www.mediclin.de ISIN: DE0006595101 WKN: 659510 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of News DGAP News Service --------------------------------------------------------------------- 408789 04.11.2015


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 609,08 645,11 673,09 659,86 673,14 704,70 730,07
EBITDA1,2 27,01 37,35 93,58 77,50 85,22 90,92 98,73
EBITDA-Marge3 4,43 5,79 13,90 11,74 12,66 12,90
EBIT1,4 6,62 15,06 22,41 0,15 11,56 19,52 12,72
EBIT-Marge5 1,09 2,33 3,33 0,02 1,72 2,77 1,74
Jahresüberschuss1 3,96 7,76 9,68 -0,04 1,49 9,72 -10,72
Netto-Marge6 0,65 1,20 1,44 -0,01 0,22 1,38 -1,47
Cashflow1,7 19,34 29,77 69,59 118,69 81,97 34,64 78,00
Ergebnis je Aktie8 0,08 0,16 0,20 -0,19 0,03 0,20 -0,23
Dividende8 0,05 0,05 0,05 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Mediclin
WKN Kurs in € Einschätzung Börsenwert in Mio. €
659510 2,540 Halten 120,65
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
9,77 19,17 0,51 19,10
KBV KCV KUV EV/EBITDA
0,62 1,55 0,17 1,42
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 06.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
02.05.2024 31.07.2024 04.11.2024 26.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-1,70% -7,70% -7,30% -25,29%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu MediClin AG  ISIN: DE0006595101 können Sie bei EQS abrufen


Pflegeeinrichtungen , 659510 , MED , XETR:MED